The Mayo Clinic has launched CANCP, a 50-gene cancer panel that assesses hotspot mutations using next-generation sequencing with the goal of predicting a patient's response to therapy. The test is available to Mayo patients and providers worldwide through Mayo Medical Laboratories.


Oxford Gene Technology has launched SureSeq Solid Tumor Panel, a 60-gene cancer panel that uses hybridization-based enrichment and is assessed via next-generation sequencing. The panel was validated on formalin-fixed paraffin embedded tissue and covers the entire exons of the 60 genes.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.